A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2026
INTERVENTION: CONDITION: Idiopathic pulmonary fibrosis ; MedDRA version: 21.1Level: PTClassification code: 10021240Term: Idiopathic pulmonary fibrosis Class: 100000004855 Therapeutic area: Diseases [C] ‐ Respiratory Tract Diseases [C08] PRIMARY OUTCOME: Main Objective: Primary end point(s): Secondary Objective: INCLUSION CRITERIA:
Epistemonikos ID: 2b6794e02cfd861f7df676c76c733bbad1e0a113
First added on: May 14, 2026